A5062424480- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Medical Imaging and Pathology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Peptidase Inhibition and Analysis
- Glioma Diagnosis and Treatment
- Biofield Effects and Biophysics
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Dementia and Cognitive Impairment Research
- Bone health and treatments
- Lung Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Advanced Image and Video Retrieval Techniques
- Complementary and Alternative Medicine Studies
- Colorectal Cancer Treatments and Studies
- Cutaneous Melanoma Detection and Management
Universität Ulm
2019-2025
Klinik und Poliklinik für Nuklearmedizin
2014-2025
Washington University in St. Louis
2023-2025
Mallinckrodt (United States)
2023-2025
Mayo Clinic in Arizona
2025
Mayo Clinic
2022-2025
WinnMed
2025
University Hospital Ulm
2018-2023
Universitätsklinik für Kinder und Jugendpsychiatrie
2023
University of Tartu
2023
<sup>177</sup>Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by the German Society Nuclear Medicine, retrospective multicenter data analysis was started in 2015 to evaluate efficacy and safety <sup>177</sup>Lu-PSMA-617 large cohort patients. <b>Methods:</b> One hundred forty-five (median age, 73 y; range, 43–88 y) mCRPC were treated 12 centers between February 2014 July...
The clinical utility of a human epidermal growth factor receptor 2 (<i>HER2</i>)–targeting Affibody molecule for detection and characterization <i>HER2</i>-positive lesions was investigated in patients with recurrent metastatic breast cancer. <b>Methods:</b> Three received <sup>111</sup>In- or <sup>68</sup>Ga-labeled DOTA<sup>0</sup>-Z<sub><i>HER2</i>:342-pep2</sub> (ABY-002). γ-Camera, SPECT, PET/CT images were compared earlier <sup>18</sup>F-FDG results. <b>Results:</b> Administration...
This ENETS guidance paper aims to provide practical advice clinicians for the diagnosis, treatment and follow-up of functioning syndromes in pancreatic neuroendocrine tumours (NET). A NET-associated syndrome is defined by presence a clinical combined with biochemical evidence inappropriately elevated hormonal levels. Different can be encountered NET patients, including insulinoma, gastrinoma as well rare glucagonoma, VIPoma, ACTHoma, PTHrPoma, carcinoid syndrome, calcitoninoma, GHRHoma...
Data regarding the diagnosis, management, and follow-up of carcinoid syndrome (CS) heart disease (CHD) were identified by searches MEDLINE database using specific terms in human studies: CS; CHD; screening; epidemiology; diagnosis; treatment; prognosis. The search results supplemented manual searching relevant journals, reference lists key articles other appropriate documents, expert opinion. All recommendations are offered on basis best available evidence, authors' experiences managing CS...
<sup>68</sup>Ga-labeled prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA) PET/CT has a proven role in staging and restaging of prostate cancer (PCA). The aims this study were to evaluate the association intraprostatic <sup>68</sup>Ga-PSMA findings PSMA expression immunohistochemical staining generate cutoff value for differentiation between normal (PN) PCA. <b>Methods:</b> data 31 patients (mean age, 67.2 y) who underwent prostatectomy preoperative PET retrospectively analyzed. On...
Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study.In our center, 2294 were screened between 2004 2014 by 68Ga (SSTR) PET/CT. Intention to treat analysis included 1048 patients, who received at least one cycle 90Yttrium or 177Lutetium-based PRRT. Progression free survival was determined SSTR-PET/CT EORTC response criteria. Adverse events CTCAE...
A key issue in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is early identification and prediction of disease progression. Clinical evaluation imaging are limited due to the lack sensitivity indolence. We assessed NETest as a predictive prognostic marker progression long-term follow-up study.GEP-NETs (n = 34) followed for median 4 years (2.2-5.4) were evaluated. WHO tumor grade/stage grade 1: n 17, 2: 14, 3: 1 (for 2, no was available); 31 (91%) stage IV. Baseline longitudinal...
Diagnostic imaging plays a pivotal role in the diagnosis, staging, treatment selection and follow-up for neuroendocrine tumors. The available diagnostic strategies are morphologic imaging, including computed tomography, magnetic resonance (MRI) ultrasound techniques, molecular scintigraphy with (111)In-pentetreotide positron emission tomography (68)Ga-DOTA-peptides, (18)F-DOPA (11)C-5-HTP. A combination of anatomic functional techniques is routinely performed to optimize sensitivity...
Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for 177Lu-PSMA-617. These statements were developed by an expert panel formed Society Nuclear Medicine (DGN) December 2015....
The complexity of the clinical management neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity clinically useful biomarkers. Limitations currently available reflect difficulties measuring an intrinsically indolent disease, resolution inadequacies inter-/intra-facility device variability that RECIST (Response Evaluation Criteria Solid Tumors) criteria are not optimal for NEN. used biomarkers they secretory (chromogranin A, serotonin, neuron-specific...
Abstract The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, half high-risk die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis key for risk-adapted guidelines presented here incorporate results national and international trials to produce recommendations diagnosing treating in German hospitals outside trials.
Summary Merkel cell carcinoma (MCC, ICD‐O M8247/3) is a rare, malignant, primary skin tumor with epithelial and neuroendocrine differentiation. The cells share many morphologic, immunohistochemical, ultrastructural features cutaneous cells. Nevertheless, the of origin MCC unclear. appears clinically as reddish to purple spherical smooth, shiny surface soft turgid, elastic consistency, usually showing rapid growth. Spontaneous often complete regressions are observed. These likely...
Pancreatic endocrine tumors are rare but among the most common neuroendocrine neoplasms of abdomen.At diagnosis many them already advanced and difficult to treat.We report on an initially inoperable malignant pancreatic tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment.This resulted significant downstaging allowed its subsequent complete surgical removal.Follow-up for eighteen months revealed remission.This is first...